SecBot SecBot
SECBOTREPLAY Home › Report › ABBV

ABBV · AbbVie reported Q2 2026 adjusted EPS of $3.65, a 1.2% beat vs

AbbVie Inc. · 8-K filed Jul 31, 2026 at 07:51 ET

At the news

BULLISHIMPACT 7/10

8-K filed Jul 31, 2026 at 07:51 ET

AbbVie reported Q2 2026 adjusted EPS of $3.65, a 1.2% beat vs. consensus of $3.61, on revenue of $16.99B (above $16.76B consensus, +10.2% YoY). The company announced a definitive agreement to acquire Apogee Therapeutics for ~$10.9B and slightly lowered its full-year adjusted EPS guidance to $13.87-$14.07 to reflect the deal's $0.14 dilutive impact, partially offset by $0.10 of operational overperformance. Strong growth in immunology (Skyrizi +24.4%, Rinvoq +24.5%) and neuroscience (+20.3%) continues to offset Humira erosion (-35.9%).

  • Q2 2026 adjusted EPS $3.65 vs. consensus $3.61 (+1.2% beat)
  • Q2 2026 revenue $16.99B vs. consensus $16.76B (+10.2% YoY reported)
  • Announced definitive agreement to acquire Apogee Therapeutics for ~$10.9B equity value
  • Full-year 2026 adjusted EPS guidance narrowed to $13.87-$14.07 from $13.91-$14.11 (includes $0.14 Apogee dilution)

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access